Core Insights - VolitionRx Limited has developed an automated Nu.Q® Cancer test that accurately detects 21 different types of cancers with high specificity and low false positive rates, potentially serving as a standalone pan-cancer test or in conjunction with other liquid biopsy technologies [1][4][5] - The company aims to disrupt the $20 billion annual market for liquid biopsy in the U.S. by providing early cancer detection solutions [2] - Volition is in discussions with large diagnostic and liquid biopsy companies to establish multiple licensing agreements, which may include milestone payments and ongoing revenue [3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics to improve early detection and monitoring of diseases, including cancer [6][7] - The company’s research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [8] Study Details - The study involved 229 cancer patients (including 70 early-stage patients) and 150 healthy subjects, demonstrating an overall AUC of 86% for detecting common fatal cancers such as lung, breast, prostate, colon, and liver cancers [4][5] - The Nu.Q® Cancer test is designed to be run on existing automated chemiluminescence platforms, making it accessible without the need for new hardware [4] Future Prospects - The company is focused on leveraging its existing technology to make Nu.Q® Cancer testing widely accessible through licensing and partnership arrangements [4] - There is potential for the Nu.Q® platform to be used not only for early cancer detection but also in the management of cancer patients, particularly in assessing treatment efficacy [5]

Core Viewpoint - VolitionRx Limited aims to transform the lung cancer diagnosis and monitoring landscape with its Nu.Q® Cancer Test, targeting the $4 billion lung cancer market [1][4]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing early detection and monitoring of diseases, including cancer [6][7]. - The company is developing cost-effective blood tests that can be administered easily, utilizing small blood samples [1][7]. Product Development - The Nu.Q® Cancer assays are designed to improve early detection and monitoring of lung cancer, potentially enhancing patient outcomes [1][3]. - A retrospective study involving 1,050 patients with Non-Small Cell Lung Cancer is set to be published, supporting the efficacy of Nu.Q® Cancer [4]. Market Opportunity - The total annual accessible market for lung cancer screening, prognostication, and minimal residual disease identification is estimated at approximately $4 billion [4]. - VolitionRx is in discussions with large diagnostics and liquid biopsy companies to establish multiple licensing agreements this year [4]. Commercial Strategy - The company's nucleosome assays can be utilized on existing automated chemiluminescence platforms, eliminating the need for new hardware [5]. - VolitionRx aims to make Nu.Q® Cancer testing widely accessible through licensing and partnership arrangements [5].

Core Viewpoint - VolitionRx Limited is participating as a silver sponsor at the 44th Annual ISICEM Congress in Brussels, showcasing its Nu.Q® H3.1 epigenetic screening technology, which has significant implications for sepsis care and critical care medicine [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics, dedicated to improving outcomes for patients with life-altering diseases through earlier detection and monitoring [9][10] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [10] Market Opportunity - The developments presented at ISICEM highlight a market opportunity exceeding $1 billion in sepsis care, positioning Volition at the forefront of advancements in critical care medicine [3] Presentations at ISICEM - Multiple presentations will feature the Nu.Q® H3.1 technology, including topics such as circulating NETs levels, functional endotyping in sepsis, and the role of H3.1 in early recognition of sepsis [3][4][5] - Notable speakers include Professor Djillali Annane and Professor Evangelos Giamarellos-Bourboulis, who will present on various aspects of sepsis and its management [4][5] Educational Impact - The ISICEM congress aims to enhance the care of critically ill patients through education and research, attracting over 5,000 participants globally [8]

Core Viewpoint - VolitionRx Limited has expanded its supply agreement with Fujifilm Vet Systems in Japan to include an automated version of its Nu.Q® Vet Cancer Test, aiming for a launch in summer 2025 [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for people and animals through early detection of diseases [7][8] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers [8] Product Details - The Nu.Q® Vet Cancer Test is designed for regular check-ups of older dogs (seven years and older) or younger high-risk breeds, priced at an average of $11 per test for central lab testing [4] - The test is non-invasive and aims to aid in early cancer detection, which is crucial as cancer is the leading cause of adult canine deaths [3][4] Market Opportunity - There are approximately seven million pet dogs in Japan, presenting a significant revenue opportunity for Volition through its partnership with Fujifilm Vet Systems, a leading provider of diagnostic tests in the country [2] - Since the launch of the Nu.Q® Vet Cancer Test in July 2024, over 1,000 veterinary hospitals in Japan have registered to use the test, indicating strong demand [2][3] Partnership Dynamics - Fujifilm Vet Systems will validate and verify the automated platform for canine cancer screening, enhancing the efficiency and throughput of the testing process [1][2] - The agreement allows Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test across its network of central reference laboratories in Japan [3]

Core Insights - VolitionRx Limited has initiated a clinical study to evaluate its Nu.Q® Cancer technology for differentiating between malignant and benign pulmonary nodules in patients undergoing low-dose computed tomography (LDCT) screening for lung cancer [1][5] - The study, in collaboration with National Taiwan University Hospital, aims to enroll 500 patients and is expected to be completed by the end of 2025 [1][2] - Previous studies indicate that the Nu.Q® Cancer test can accurately identify malignant nodules with high sensitivity, which could lead to its inclusion in national lung cancer screening programs [4][5] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection of diseases [8][9] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers [9] - Volition's research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [9] Industry Context - Lung cancer is a leading cause of cancer-related deaths globally, and LDCT is recognized as the gold standard for lung cancer screening [3] - The high sensitivity of LDCT can lead to false positives and unnecessary invasive procedures for patients with benign nodules, highlighting the need for more accurate diagnostic tools [3][6] - A blood-based test that can distinguish between cancerous and non-cancerous nodules would significantly enhance clinical practice and lung cancer screening programs [7]

Core Insights - VolitionRx Limited has signed an agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study, marking a significant milestone for the company [1][3] - The study is expected to generate substantial revenue for Volition over a 12-18 month period, with further projects under discussion [2] Company Developments - The Nu.Q® Discover program offers advanced assays for rapid epigenetic profiling, aiding drug developers and scientists from discovery to market readiness [1][9] - The collaboration allows Volition to leverage its nucleosome expertise to enhance clinical research, potentially improving patient selection for treatment [5][6] Market Positioning - This partnership highlights the growing recognition of Volition's nucleosome-based biomarkers in clinical development, aligning with the company's long-term goal of enabling precision therapy [4][7] - The application of Nu.Q® Discover in clinical trials positions Volition to expand its role in precision medicine and targeted therapeutic approaches [8]

Core Points - VolitionRx Limited will participate in the 97th Annual Western Veterinary Conference (WVC) from March 2-5, 2025, in Las Vegas, NV, attracting approximately 20,000 veterinary professionals [1][5] - The company will showcase its Nu.Q® Vet Cancer Test, which aids in the detection of seven common cancers in dogs, emphasizing its accessibility, affordability, and ease of use [3][4] - Volition's strategic commercialization efforts in North America aim to expand awareness and education regarding the Nu.Q® Vet Cancer Test [3] Event Details - Presentation 1: "Detect, Treat, Monitor: Navigating the Canine Cancer Journey with Nu.Q® Vet Cancer Test" by Dr. Sue Ettinger on March 3, 2025, from 2:00 PM to 2:50 PM [4] - Presentation 2: "Utilizing the Nu.Q® Vet Cancer Test in Practice" by Dr. Brett Cordes on March 4, 2025, from 10:30 AM to 11:00 AM [4] - Presentation 3: "The Nu.Q® Vet Cancer Test - Early Detection with Canine Cancer Screening" by Dr. Tom Butera on March 5, 2025, from 12:10 PM to 1:00 PM [4] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring [5][6] - The company is developing cost-effective blood tests to diagnose and monitor various diseases, including cancers and conditions associated with NETosis, such as sepsis [6][7] - Volition's research and development activities are centered in Belgium, with additional facilities in the U.S. and London [7]

Core Insights - VolitionRx Limited has announced its first commercial sale of a High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps (NETs) activation and inhibition in real time, aiding in the development of new therapeutics for sepsis and related diseases [1][4] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and dedicated to improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring [8][9] Technology and Innovation - The High Throughput NETs model represents a significant breakthrough in understanding neutrophil biology, allowing for more precise measurement of NETs formation in whole blood, which is crucial for therapeutic interventions [2][3] - The innovative approach addresses technical limitations in previous research by measuring NETs directly in whole blood, avoiding alterations in neutrophil responses caused by isolation procedures [3][7] Market Relevance - Sepsis, characterized by a dysregulated host response to infection, results in approximately 370,000 deaths annually in the U.S., highlighting the urgent need for effective diagnostic and therapeutic solutions [4][5] - The understanding of NETs has become increasingly relevant in disease contexts, with overproduction leading to tissue damage and disease progression during inflammatory responses [5][6] Research and Development - Volition is developing cost-effective blood tests aimed at diagnosing and monitoring a range of diseases, including cancers and conditions associated with NETosis, which could significantly improve patient outcomes [6][9]

HENDERSON, Nev., Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here. Dr. Retter will focus on Nu.Q® NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and ...

HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.Findings published in the paper currently undergoing peer review and accessible on MEDRXIV, demonstrate Nu.Q® NETs H3.1 is a promising novel bioma ...